cremophor el has been researched along with tyrosine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Höke, A; Jack, C; Lambrinos, GL; Melli, G; Ringkamp, M | 1 |
| Bushman, J; Garbuzenko, OB; Gounder, MK; Kohn, J; Minko, T; Sheihet, L | 1 |
2 other study(ies) available for cremophor el and tyrosine
| Article | Year |
|---|---|
Erythropoietin protects sensory axons against paclitaxel-induced distal degeneration.
Topics: Animals; Antineoplastic Agents, Phytogenic; Axons; Cells, Cultured; Dose-Response Relationship, Drug; Drug Carriers; Erythropoietin; Female; Ganglia, Spinal; Glycerol; Humans; Injections, Intraperitoneal; Mice; Nerve Degeneration; Neurons, Afferent; Neuroprotective Agents; Paclitaxel; Recombinant Proteins; Tubulin; Tyrosine | 2006 |
Paclitaxel in tyrosine-derived nanospheres as a potential anti-cancer agent: in vivo evaluation of toxicity and efficacy in comparison with paclitaxel in Cremophor.
Topics: Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Drug Carriers; Female; Glycerol; Humans; Maximum Tolerated Dose; Mice; Mice, Nude; Nanospheres; Neoplasms; Paclitaxel; Pharmaceutical Vehicles; Tyrosine; Xenograft Model Antitumor Assays | 2012 |